We found that low socioeconomic status in adulthood was related to adverse changes in control beliefs during the six year follow up (results not shown), suggesting that adult socioeconomic conditions further contribute to beliefs of low control. More information is needed on the specific socioeconomic correlates that induce beliefs of low control as these may be easier to modify than the beliefs themselves. Low job control may be one of these conditions. 5 Other studies with larger numbers are needed to examine the behavioural or psychophysiological pathways through which perceived control affects mortality. Our findings emphasise that only by examining psychological mechanisms more thoroughly can we determine the complex pathways through which social structure affects individual disease and mortality.
Contribution of job control and other risk factors to social variations in coronary heart disease incidence. Lancet 1997;349:235-9.
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Cost effectiveness analysis of inhaled anticholinergics for acute childhood and adolescent asthma
Joanne Lord, Francine M Ducharme, Ronald J Stamp, Peter Littlejohns, Rachel Churchill A recent systematic review by the Cochrane Airways Group showed that adding multiple doses of anticholinergics to 2 agonists is safe and effective in improving lung function and avoiding hospital admission for school aged children and adolescents attending casualty departments with severe acute asthma. 1 The estimated reduction in the risk of admission was 9.4% (0.4% to 18.4%). This intervention presumably improves bronchodilatation until systemic corticosteroids take effect. Evidence of cost effectiveness, however, is lacking. To clarify whether scarce health resources should be spent on this intervention we conducted an economic evaluation.
Methods and results
We used various assumptions to estimate the financial implications of treatment (see table on the BMJ 's website). The costs of drug administration were not included, as anticholinergics are always given with 2 agonists and involve little additional manipulation. The cost of nebulisers, other drugs, and the casualty attendance were also excluded. No consideration was given to possible changes in length of stay in casualty. The effect of changing the various assumptions was tested by simple, one way, sensitivity analysis, and by multivariate probabilistic sensitivity analysis.
2
The latter is a simulation approach that enables estimation of uncertainty ranges containing 95% of replicated results. 3 We estimated that treatment would cost about £8 (uncertainty range £1 to £47) per admission avoided (table) . This implies a net saving of £80 (£0 to £157) per severe case treated. Varying the risk reduction within 95% confidence limits varied the mean net saving from £3 to £157 per severe case treated. More precision is expected when the Cochrane review is updated. Varying the cost of hospital admissions within the interquartile range for English providers (£620 to £907) varied the mean savings from £58 to £85 per severe case treated. Changes to the dose and unit cost of ipratropium had very little effect on the results.
Further assumptions were used to extrapolate the findings to a national level. About 7200 children aged 5-15 years are admitted from casualty with a diagnosis of asthma each year (hospital episode statistics 1988 to 1996) . About 40% of children in this age group attending casualty with asthma are admitted. 4 We assumed that 50% of people with asthma attending casualty have severe asthma. 5 The rate of uptake of the review recommendations was assumed to be 5% a website extra A year; therefore an additional 5% of eligible patients would be treated in the first year, 10% in the second year, and so on. If doctors treated patients with mild or moderate asthma, this would add to treatment costs with no evidence of clinical benefit. We assumed that for every five patients with severe asthma who were treated, one patient with mild or moderate asthma would be treated. Costs were discounted at an annual rate of 6%.
Net savings were estimated to be £437 800 ( − £3700 to £1 078 100) over five years in England. An increase in the number of patients for whom treatment is indicated, or in the proportion of eligible patients who are treated, leads to a proportionate increase in savings. For example, if all eligible patients were to be treated, after five years the estimated savings would be quadrupled. A reduction in the annual discount rate from 6% to 3% leads to an increase of £47 600 in expected savings. Increasing the ratio of inappropriate to appropriate treatment from 20% to 100% leads to a small decrease (£2800) in expected savings.
Comment
The addition of multiple dose anticholinergics to inhaled 2 agonists for children and adolescents attending casualty with severe acute asthma would result in savings in health service resources. This finding is robust to changes in modelling assumptions, although some uncertainties remain. The personal value of the health effects and avoided hospital admissions provide additional benefits that have not been quantified in this analysis.
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A memorable patient
Unforeseen consequences
It was not long after I had arrived to take over a singlehanded practice in a rural part of Ireland that I first met Jean. I was struck by her big hands, jutting chin, and rather waxy facial features. The fact that she had hypertension and diabetes lent support to my clinical impression of acromegaly and that this had gone unnoticed in over three years of attendance at the hospital medical outpatient department added to the glow of satisfaction when the diagnosis was confirmed by an endocrinologist. Jean was glad to have a diagnosis but was nervous of the prospect of surgery when a computed tomogram showed the pituitary tumour responsible. Her daughter had died some years earlier of a brain tumour and neurosurgery was linked in her mind with this. Thanks to a skilled neurosurgeon (the same man who had operated on her daughter) everything went well and Jean had her tumour resected.
Six months later at routine follow up, a scan raised the possibility of a middle cerebral artery aneurysm, an unrelated condition which might never have been diagnosed normally. An angiograph confirmed bilateral middle cerebral artery aneurysms and Jean was admitted to have them clipped. The right artery was clipped but she developed a hemiparesis which resolved fairly quickly. It was decided to readmit her at a later date to clip the left side.
The experience frightened Jean and she was dubious about further surgery. I spoke with the neurosurgeon who said that about one patient in 20 would develop spasm following surgery and this could give a stroke-like effect. However, he thought that the risk of surgery was less than the risk of an untreated aneurysm. Jean made a pilgrimage to Lourdes.
Two months later Jean decided to go ahead with the operation. Postoperative recovery was slow and unfortunately she developed another hemiparesis dysphasia and became completely dependent on nursing staff. Now three yeas on, Jean is in a nursing home. Her hemiparesis has resolved considerably, but she is unable to speak and seems to have a global dysphasia. Her husband, Michael, attends me regularly. He lives alone about 15 miles from the nursing home and visits Jean nearly every day. He blames no one for what has happened. He accepts that the doctors made their decisions in good faith and after careful consideration.
If I come across another patient with signs and symptoms like Jean I would undoubtedly refer that patient to an endocrinologist. However, I feel sad and humbled by Michael's loneliness and cannot help wondering whether or not Jean might still be living with him albeit unaware of her acromegaly and dilated middle cerebral arteries, were it not for the arrival of the new doctor and his clever diagnosis.
Garrett Igoe general practitioner, Virginia, County Cavan, Republic of Ireland
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